Cited by 282Cancer Genomics and DiagnosticsPancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas

Open access

Zill, Oliver A., Greene, Claire, Sebisanovic, Dragan, Siew, Lai Mun, Leng, Jim, Vu, Mary, Hendifar, Andrew E., Wang, Zhen, Atreya, Chloe E., Kelley, Robin K., Van Loon, Katherine, Ko, Andrew H., Tempero, Margaret A., Bivona, Trever G., Munster, Pamela N., Talasaz, AmirAli, Collisson, Eric A.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0274PMC PMC4592417

Published version of a preprint

Open this paper in CoChat — free account

Abstract

UNLABELLED: Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA) sequencing may enable a precision oncology approach in this setting. We attempted to prospectively analyze 54 genes in tumor and cfDNA for 26 patients. Tumor sequencing failed in 9 patients (35%). In the remaining 17, 90.3% (95% confidence interval, 73.1%-97.5%) of mutations detected in tumor biopsies were also detected in cfDNA. The diagnostic accuracy of cfDNA sequencing was 97.7%, with 92.3% average sensitivity and 100% specificity across five informative genes. Changes in cfDNA correlated well with tumor marker dynamics in serial sampling (r = 0.93). We demonstrate that cfDNA sequencing is feasible, accurate, and sensitive in identifying tumor-derived mutations without prior knowledge of tumor genotype or the abundance of circulating tumor DNA. cfDNA sequencing should be considered in pancreatobiliary cancer trials where tissue sampling is unsafe, infeasible, or otherwise unsuccessful. SIGNIFICANCE: Precision medicine efforts in biliary and pancreatic cancers have been frustrated by difficulties in obtaining adequate tumor tissue for next-generation sequencing. cfDNA sequencing reliably and accurately detects tumor-derived mutations, paving the way for precision oncology approaches in these deadly diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0274

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J. W., Wasan, H. S., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T. J., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,423
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“As a result, most genomic research in PDA has centered around tumor-derived cell lines or xenografts in lieu of direct tumor sequencing(7), and expert bodies currently make no recommendations regarding molecular profiling for clinical decision-making in PDA(8), despite potentially sensitive subsets identified by seque…”
Background
Pancreatic adenocarcinoma
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348

Show all 31 references

Sorted by citations

Items 201–281 of 281

Genomic alterations in tumor tissue and ctDNA from Chinese pancreatic cancer patients.
Xiong, A., Ma, N., Wei, G., Li, C., Li, K., & Wang, B. (2021) · PubMed Central · Cited by 5
Cell-free DNA as a prognostic and predictive biomarker in resectable distal common bile duct cancer
Shyr, B., Chen, S., Shyr, Y., Wang, S., & Shyr, B. (2023) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000923 · Cited by 5
Primary liver cancer genome sequencing: translational implications and challenges.
Ziogas, D. E., Kyrochristos, I. D., Glantzounis, G. K., Christodoulou, D. K., Felekouras, E. S., & Roukos, D. H. (2017) · PubMed · doi:10.1080/17474124.2017.1356227 · Cited by 5
EGFRExon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed byT790M-Mediated Resistance
Cecchini, M., Sklar, J., & Lacy, J. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0151 · Cited by 5
Circulating tumor DNA in management of primary liver malignancy: A review of the literature and future directions
Tocci, N. X., Wehrle, C. J., Sun, K., Jiao, C., Hong, H., Gross, A. R., Allkushi, E., Uysal, M., Linganna, M. W., Stackhouse, K., et al. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27825 · Cited by 4
Targeted therapies in advanced biliary malignancies: a clinical review
Grewal, U. S., Gaddam, S. J., Beg, M. S., & Brown, T. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2387612 · Cited by 4
Duodenal Fluid Analysis as a Rewarding Approach to Detect Low-Abundance Mutations in Biliopancreatic Cancers
Tavano, F., Latiano, A., Palmieri, O., Gioffreda, D., Latiano, T. P., Gentile, A., Tardio, M., Latiano, T. P., Gentile, M., Terracciano, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158436 · Cited by 4
Tumor-educated platelet, a potential liquid biopsy biosource in pancreatic cancer: A review
Zaki‐Dizaji, M., Taheri, Z., Heiat, M., & Hushmandi, K. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155986 · Cited by 4
Circulating Tumour Cells
Georgiadis, K. L., Simpson, K., Ayub, M., Brady, G., Valle, J. W., Jørgensen, C., & Dive, C. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_62-1 · Cited by 4
Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges
Yao, G., Zhang, Y., Li, H., Teng, L., Man, Y., Wang, S., Liu, C., Fan, Y., & Chen, D. (2026) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000999 · Cited by 3
Liquid biopsy for biliary tract cancer: available evidence and future research directions
Erul, E., Ricci, A. D., Mura, M. D., Cazzato, G., Massafra, R., Tolunay, P. K., Ürün, Y., & Rizzo, A. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2670701 · Cited by 3
A novel KRAS exon 2 drop-off digital PCR assay for mutation detection in cell-free DNA of cancer patients
Nard, B. A.-D., Geissmann, M., Akhoundova, D., Pistoni, C., Brezina, T., Zoche, M., Weber, A., Hussung, S., & Fritsch, R. (2025) · Diagnostic Pathology · doi:10.1186/s13000-025-01637-y · Cited by 4
The Cytomorphologic and Molecular Assessment of Bile Duct Brushing Specimens
Hilburn, C. F., & Pitman, M. B. (2022) · Surgical pathology clinics · doi:10.1016/j.path.2022.05.002 · Cited by 3
Genomic Landscape of Advanced Solid Tumors in Middle East and North Africa Using Circulating Tumor DNA in Routine Clinical Practice
Dawood, S. S., Sandhir, N., Akasheh, M., Khoury, M. E., Otsmane, S., Al-Nassar, M., Abulkhair, O. A. M., Farhat, F., & Olsen, S. (2024) · Oncology · doi:10.1159/000541571 · Cited by 3
How Can Next-Generation Diagnostics Aid Pancreatic Adenocarcinoma Treatment?
Zhang, S. Q., & Catenacci, D. V. T. (2016) · Future Oncology · doi:10.2217/fon.15.353 · Cited by 3
Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients
Shim, H., Kwon, M. J., Park, I. H., Kim, M. K., Cho, E., Lee, J., Lee, S., Sim, S. H., Lee, K. S., Kim, Y., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-4881 · Cited by 3
Prediction of Pancreatic Cancer Risk and Therapeutic Response with Next-Generation Sequencing
Kyrochristos, I. D., Ziogas, D. E., Glantzounis, G. K., & Roukos, D. H. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0315 · Cited by 3
Targeting dynamics of subclones of GI, liver and pancreatic cancers
Ziogas, D. E., Glantzounis, G. K., Liakakos, T., & Roukos, D. H. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1179578 · Cited by 3
Liquid biopsy & surgery: What's ahead?
Hagen, M. E., Douissard, J., Ris, F., & Toso, C. (2021) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2021.05.011 · Cited by 3
Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic cancer
Petersson, A., Svensson, M., Hau, S. O., Bergström, R., Lindberg, J., Mayrhofer, M., Chattopadhyay, S., Eberhard, J., Heidenblad, M., Leandersson, K., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-22369-5 · Cited by 2
Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers
Ma, H., Qammar, S., Wang, J.-M., Zhai, A., Li, F., & Hu, H. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70281 · Cited by 2
A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation
Kamath, S. D., Lin, X., & Kalyan, A. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0210 · Cited by 2
Diagnostic methods for pancreatic cancer and their clinical applications (Review)
Zhao, J., Wang, J., Gu, Y., Huang, X., & Wang, L. (2025) · Oncology Letters · doi:10.3892/ol.2025.15116 · Cited by 5
Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing
Balendran, S., Kieler, M., Liebmann‐Reindl, S., Unseld, M., Bianconi, D., Prager, G. W., & Streubel, B. (2021) · Cancer Management and Research · doi:10.2147/cmar.s308029 · Cited by 2
Overcoming diagnostic issues in precision treatment of pancreatic cancer
Löhr, M. J., Kordes, M., Rutkowski, W., Heuchel, R. L., Gustafsson‐Liljefors, M., Russom, A., & Nilsson, M. F. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1476061 · Cited by 2
Circulating Tumor Cells
Georgiadis, K. L., Simpson, K., Ayub, M., Brady, G., Valle, J. W., Jørgensen, C., & Dive, C. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_62 · Cited by 2
Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer
Shyr, B., Shyr, B., Chen, S., Chang, S., Shyr, Y., & Wang, S. (2021) · Cancers · doi:10.3390/cancers13102313 · Cited by 2
Management of Cancer Recurrence
Strobel, O., & Büchler, M. W. (2018) · doi:10.1002/9781119188421.ch119 · Cited by 2
Utility of circulating tumor DNA in secondary liver malignancies: What we know and what is to come
Wehrle, C. J., Tocci, N. X., Sun, K., Jiao, C., Hong, H., Gross, A. R., Allkushi, E., Uysal, M., Linganna, M. W., Stackhouse, K., et al. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27838 · Cited by 1
Prolonged response to osimertinib in three patients with refractory metastatic pancreatic adenocarcinomas with EGFR exon 19 deletion: a case report and literature review
Vigié, T., Perrier, A., Chanez, B., de Martino, J., Favre, L., Coulet, F., Bachet, J., Guillerm, E., & Mas, L. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241312078 · Cited by 1
Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer
Shimizu, H., Suzuki, R., Asama, H., Sato, K., Osawa, K., Ohira, R., Kudo, K., Sugimoto, M., & Ohira, H. (2025) · Cancers · doi:10.3390/cancers17183071 · Cited by 2
Circulating tumor cell and oncosome subtypes in portal and peripheral venous circulations may be used for diagnosis and prognostication of pancreatic cancer
Shishido, S. N., Suresh, D., Mason, J., Liu, Q. Y., Park, K. S., Watson, R. R., Nissen, N., Gaddam, S., Lo, S. K., Pandol, S. J., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01165-4 · Cited by 1
Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience
Abidoye, O., Pirozzi, A., Okano, N., Raupach, E. A., Elliott, N. M., Guzman, E., Urquieta, B., Rone, K., Andrews, K., Wu, C. S.-Y., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00621 · Cited by 1
Pancreatic Cancer Biomarkers in Circulation
Dakubo, G. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-48360-3_9 · Cited by 1
Liquid Biopsy for Early Detection of Pancreatic Cancer
Takai, E., & Yachida, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-2486-3_5 · Cited by 1
Non-invasive Prenatal Testing (NIPT)
Manning, C., & Abbott, M. (2019) · doi:10.2310/obg.19129 · Cited by 1
Treatment of Recurrent Pancreatic Cancer After Surgery
Strobel, O., Niesen, W., & Büchler, M. W. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_58 · Cited by 1
Morphologic and molecular diagnostic criteria of malignancies in biliary strictures.
Albertini, E., Miranda, L., Maloberti, T., de Biase, D., & Vasuri, F. (2025) · PubMed · doi:10.14670/hh-18-811 · Cited by 1
Treatment of Recurrent Pancreatic Cancer After Surgery`
Strobel, O., Niesen, W., & Büchler, M. W. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_58-1 · Cited by 1
Circulating Molecular and Cellular Biomarkers in Cancer
Chiodi, I., Scovassi, A. I., & Mondello, C. (2017) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781119023647.ch16 · Cited by 1
Molecular Landscape of Pancreatic Cancer: Challenges and Clinical Implications
Kyrochristos, I. D., Ziogas, D. E., Glantzounis, G. K., & Roukos, D. H. (2017) · Future Oncology · doi:10.2217/fon-2017-0335 · Cited by 1
Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic
Loft, M., Jalali, A., Gibbs, P., Tie, J., & Western Health, F. (2019) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2019.15.1.33 · Cited by 1
Unmet needs in basic and translational research in Cholangiocarcinoma
Cadamuro, M., Macı́as, R. I. R., Strain, A. J., Strazzabosco, M., Simioni, P., Marı́n, J. J. G., & Fabris, L. (2021) · Liver Cancer International · doi:10.1002/lci2.39 · Cited by 1
Screening for Pancreatic Cancer: Current Status and Future Directions
Puri, A., Chang, J. C. S., & Kundranda, M. N. (2017) · European Medical Journal · doi:10.33590/emj/10313242 · Cited by 1
Association of Circulating Tumor DNA Fraction Analysis with Clinical and Pathologic Characteristics in Endometrial and Ovarian CancerPreprint
Vater, M., Garrett, A. A., Collier, K. A., Rose, P. G., Tinoco, G., Strahan, A., Stover, D. G., & Mahdi, H. (2023) · Preprints.org · doi:10.20944/preprints202311.1471.v1 · Cited by 1
Early Biomarkers for Pancreatic Cancer: A Quest for Survival, Review on the Most Effective Approaches at PresentPreprint
Bestari, M. B., Joewono, I. R., & Syam, A. F. (2023) · Preprints.org · doi:10.20944/preprints202312.2276.v1
Is Circulating Tumor DNA (Ctdna) Use Ready For Prime Time? Applications and Challenges of Ctdna in the Era of Precision Oncology
Davis, A., Chae, Y., & Giles, F. J. (2017) · Chemotherapy Open access · doi:10.4172/2167-7700.1000230
Tumor Markers in Pancreatic Malignancies
Hamada, S., Masamune, A., & Shimosegawa, T. (2018) · doi:10.1002/9781119188421.ch100
GENETIC EVOLUTION AND PROGNOSTIC DETERMINANTS OF PANCREATIC CANCER ON LONGITUDINAL LIQUID BIOPSIES
Bernard, V. (2018) · Digital Commons-TMC (Texas Medical Center)
Developing Targeted Therapy against Pancreatic Cancer
Kaushik, G. (2019) · DigitalCommons@UNMC
Biomarkers of Pancreatic Cancer
Kishikawa, T., Tada, M., Otsuka, M., & Koike, K. (2019) · Springer eBooks · doi:10.1007/978-981-13-7295-7_9
Circulating Tumor DNA as a Novel Biomarker for Pancreatic Cancer
Berger, A. W., & Kleger, A. (2020) · Molecular and translational medicine · doi:10.1007/978-3-030-49476-6_7
Liquid Biopsy: A New Diagnostic Strategy and Not Only for Lung Cancer?
Scarpino, S., & Malapelle, U. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94838
Incorporating Circulating Biomarkers into Clinical Trials
Jankú, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_14
Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology
Comparetto, C., & Borruto, F. (2020) · Journal of cancer research updates · doi:10.30683/1929-2279.2020.09.06
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer
Valente, M., Covre, A., Giacomo, A. M. D., & Maio, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-37482-2_50-1
Toward Early Detection Of Pancreatic Cancer
Sharagi, O. (2019) · doi:10.31979/etd.2tzh-x2j9
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer
Valente, M., Covre, A., Giacomo, A. M. D., & Maio, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_50
Data from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Lapin, M., Edland, K. H., Tjensvoll, K., Oltedal, S., Austdal, M., Garresori, H., Rozenholc, Y., Gilje, B., & Nordgård, O. (2023) · doi:10.1158/1078-0432.c.6533206.v1
Data from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Lapin, M., Edland, K. H., Tjensvoll, K., Oltedal, S., Austdal, M., Garresori, H., Rozenholc, Y., Gilje, B., & Nordgård, O. (2023) · doi:10.1158/1078-0432.c.6533206.v2
Supplementary Experimental Methods from Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M. H., Raghavan, S., Kim, J., Brais, L. K., Ragon, D. Y., et al. (2023) · doi:10.1158/2159-8290.22532626.v1
Data from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Lapin, M., Edland, K. H., Tjensvoll, K., Oltedal, S., Austdal, M., Garresori, H., Rozenholc, Y., Gilje, B., & Nordgård, O. (2023) · doi:10.1158/1078-0432.c.6533206
Management of Cancer Recurrence
Strobel, O., Loos, M., & Büchler, M. W. (2023) · doi:10.1002/9781119876007.ch155
Liquid Biopsies for Pancreatic Cancer: Is It Ready for Prime Time?
Monahan, K., & George, B. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_7
Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlationsPreprint
Theparee, T., Akroush, M., Sabatini, L. M., Mangold, K. A., Joseph, N. E., Stocker, S. J., Freedman, A. A., Talamonti, M. S., & Kaul, K. L. (2023) · Research Square · doi:10.21203/rs.3.rs-3442924/v1
Circulating Tumor DNA in Lymphoma
Huang, J., & Gocke, C. D. (2023) · Molecular pathology library · doi:10.1007/978-3-031-46842-1_25
Bile liquid biopsy is a useful modality for molecular diagnosis of cancerous tumors in pancreatic head lesionsPreprint
Ando, M., Ito, S., Aoki, S., Zhang, J., Hirano, N., Kashiwagi, R., Murakami, K., Yoshimachi, S., Sato, H., Kusaka, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4228560/v1
Molecular profiling and next-generation sequencing applications in transplant oncology
Soliman, N., Victor, D. W., & Connor, A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21901-6.00013-6
Role of ctDNA in the Management of Gallbladder Cancer
Kundranda, M. N., & Yeung, Z. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-76746-3_15
The ctDNA revolution: Insights on cancer care: A narrative review
Gohil, K. M., Reddy, J. P., Mulla, S. K., Singh, R., Shah, R., & Gohil, S. M. (2024) · Bioinformation · doi:10.6026/9732063002001287
Role of genomics in liver transplantation for cholangiocarcinoma
Soliman, N., Maqsood, A., & Connor, A. A. (2025) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001209
Comprehensive genetic profiling using tissue and blood in locally advanced tumors
Fujiyoshi, K., Sugihara, R., Miyamoto, N., Watanabe, Y., Sudo, T., Numata, S., Akiba, J., Abe, H., Ichinose, Y., Inoue, K., et al. (2025) · Oncology Reports · doi:10.3892/or.2025.8967
Biomarkers in liver disease and transplantation: Outlook for precision medicine
Mammadov, R. A., Janmaat, V. T., Verhoeven, C. J., IJzermans, J. N. M., Peppelenbosch, M. P., van der Laan, L. J. W., & Roest, H. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-823524-9.00006-x
Aspect pré analytique et intérêt clinique de la détection d'ADN tumoral circulant par PCR digitale en oncologie digestive
Sefrioui, D. (2017) · doi:10.70675/58257576zef53z49b3zb16bz3309b1154d62
Intérêt de l'étude des HSP70-exosomes dans le diagnostic et le suivi du cancer
Chanteloup, G. (2020) · theses.fr (ABES) · doi:10.70675/ae1cca2az7e99z41aazbb58z8b3f455c016a
Promising molecular genetic diagnostic technologies in patients with pancreatic ductal adenocarcinoma
Shabunin, A. V., Tavobilov, M. M., Bagateliya, Z. A., Lebedev, S. S., Kobzev, Y. N., Lantsynova, A. V., Abramov, K. A., Kudryash, E. B., & Aladin, М. N. (2026) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2026-25-1-18-27
Evidence Mapping of ctDNA Reporting in Pancreatic Ductal Adenocarcinoma: Toward a Shared Quantitative Language for ctDNA
Croagh, D. G., & Aslani, S. (2026) · Cancers · doi:10.3390/cancers18081318
Precision Medicine in Gastric, Gastroesophageal, Pancreatic, and Biliary Tract Tumors
Fernández-Aceñero, M. J. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_5
Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large‐Cohort Study
You, T. T., Tang, H., Yuan, M., Song, D., Wang, C., Ying, J., Chen, R. R., Bai, C., Cheng, Y., & Wang, Y. (2026) · MedComm · doi:10.1002/mco2.70829 · Cited by 1
Clinical applications of selected liquid biopsy biomarkers in pancreatic cancer with a focus on ctDNA CTCs and exosome derived biomarkers
Mi, L., Wang, Y., Xu, H., Li, S., Duan, Y., Nie, R., Huixian, Z., Li, B., Wang, Z., Ren, L., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-05563-3
Prognostic Value and Longitudinal Dynamics of Multigene Circulating Tumor DNA in Advanced Pancreatic Cancer Treated with 5-Fluorouracil-Based Chemotherapy
Lee, G. Y., Chun, J. W., Lee, D.-E., Jang, J.-H., Lee, W. J., Kim, H.-P., Lee, S., Yoo, C., & Kong, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198668

Authors: Zill, O. A., Greene, C., Sebisanovic, D., Siew, L. M., Leng, J., Vu, M., Hendifar, A. E., Wang, Z., Atreya, C. E., Kelley, R. K., Van Loon, K., Ko, A. H., Tempero, M. A., Bivona, T. G., Munster, P. N., Talasaz, A., & Collisson, E. A.
Affiliations: University of California, San Francisco (US)
Guardant (United States) (US)
University of South Alabama (US)
Cedars-Sinai Medical Center (US)
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Corresponding author: Collisson, Eric A.
ORCID: Zill, Oliver A.
Leng, Jim
Hendifar, Andrew E.
Atreya, Chloe E.
Kelley, Robin K.
Ko, Andrew H.
Tempero, Margaret A.
Bivona, Trever G.
Talasaz, AmirAli
Collisson, Eric A.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-09-30
Volume: 5
Issue: 10
Pages: 1040-1048
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0274
PMC: PMC4592417
OpenAlex: W2113754052
Cited by: 282
References: 31
Citations by year: 2026: 11 · 2025: 20 · 2024: 16 · 2023: 29 · 2022: 21 · 2021: 31 · 2020: 29 · 2019: 30 · 2018: 35 · 2017: 31 · 2016: 21 · 2015: 8
FWCI: 10.46
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (DP2CA174497, K08CA175153)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords: cell-free DNA sequencing, circulating tumor DNA, pancreatic cancer, biliary tract cancer, precision oncology, tumor mutation detection, diagnostic accuracy, tumor markers, liquid biopsy
MeSH terms: Bile Duct Neoplasms, Carcinoma, DNA, Neoplasm, Humans, Mutation, Neoplasm Staging, Pancreatic Neoplasms, Prognosis, Sensitivity and Specificity, Biomarkers, Tumor, Reproducibility of Results, Disease Progression, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Mutation Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks